Biohaven, Yet Another Rival To Argenx In Autoimmune Drugs, Just Rocketed 33%

Biohaven 2Q Loss/Shr $1.32 >BHVN

Biohaven Told That FDA Won't Review NDA Application for Troriluzole

Biohaven, A Top 2% Stock, Exits 'Stealth Mode' And Hits A Record High

Biohaven 1Q Loss/Shr $1.03 >BHVN

Biohaven Buys Exclusive Rights for Brain Disorder Agent BHV-8000 From Hangzhou Highlightll

Pfizer Rolls the Dice on Seagen in $43 Billion Deal. The Risks It Faces.

Pfizer Rolls the Dice on Seagen in $43 Billion Deal. The Risks It Faces.

Get ready for more merger mania in the pharma sector for the rest of the year

Who Will Lead Biogen? Here Are Some Likely Picks.

Pfizer's New Drug Yields Encouraging Treatment Data

It's Another Bad Week for Biotech Stocks. Relief Could Come Next Month.

Pfizer Is Spending $11.6 Bln on Biohaven. Its Plans Point to a Lot More M&A.

Pfizer to Buy Rest of Biohaven for $11.6 Billion

Pfizer to Buy Biohaven Pharmaceuticals for $11.6 Billion

Why Biohaven Pharma’s Prospects Look Healthy